- Valirx
- 26 August 2025 12:35:46
Source: Sharecast
The AIM-traded life sciences company said Blue Ribbon would initially hold intellectual property for Val201, licensed from Cancer Research Horizons in 2010, with plans to file new application-based patents as development work progresses.
A technical and market review confirmed the commercial potential for Val201 in prostate cancer treatment, and a critical path plan is now in place to expedite improvements and position the therapy for clinical partnering.
ValiRx also announced it has received a notice of allowance for a Canadian ‘medical use’ patent covering the Val201 peptide for treating non-cancerous conditions such as endometriosis.
“We have an opportunity to build a broader prostate cancer focussed portfolio based on current and future pan cancer assets that can be applied in this indication,” said chief executive Mark Eccleston.
“Having worked on the original pre-clinical development of Val201, I am pleased that there is still a market opportunity for this asset, and we intend to rapidly complete the planned work required to get this back into the clinic in new and improved form.”
Tony Hickson, chief business officer at Cancer Research Horizons, added that Val201 had a “unique mechanism of action” and could be positioned to address resistant forms of cancer, as well as potentially earlier stages of the disease to mitigate the side effects seen under hormone ablation.
“We are pleased that ValiRx and Blue Ribbon Bio will continue with the development of a version of the therapy optimised for clinical impact.”
At 1119 BST, shares in ValiRx were up 2.1% at 0.54p.
Reporting by Josh White for Sharecast.com.